| Exploring a model-based analysis of patient derived xenograft studies in oncology drug development J Dickinson, M de Matas, PA Dickinson, HB Mistry PeerJ 9, e10681, 2021 | 7 | 2021 |
| Determining bioequivalence possibilities of long acting injectables through population PK modelling P Gajjar, J Dickinson, H Dickinson, L Ruston, HB Mistry, C Patterson, ... European Journal of Pharmaceutical Sciences 179, 106296, 2022 | 6 | 2022 |
| BI KRASmulti, a first-in-class, orally bioavailable and direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in KRAS G12V-driven preclinical models DH Peng, A Tedeschi, L Herdeis, F Savarese, F Rocchetti, P Johannes, ... MOLECULAR CANCER THERAPEUTICS 22 (12), 2023 | | 2023 |
| Abstract A087: BI KRASmulti, a first-in-class, orally bioavailable and direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in KRAS G12V … DH Peng, A Tedeschi, L Herdeis, F Savarese, F Rocchetti, P Johannes, ... Molecular Cancer Therapeutics 22 (12_Supplement), A087-A087, 2023 | | 2023 |
| Radius additivity score: a novel combination index for tumour growth inhibition in fixed-dose xenograft studies N Melillo, J Dickinson, L Tan, HB Mistry, HJ Huber Frontiers in Pharmacology 14, 1272058, 2023 | | 2023 |
| Population PK modelling as an alternative route to bioequivalence P Gajjar, J Dickinson, H Dickinson, L Ruston, HB Mistry, C Patterson, ... British Journal of Pharmacy 7 (2), S1-S2, 2022 | | 2022 |
| Streamlined Pathways to Clinical Success through Integrated Modelling J Dickinson AAPS PharmSci 360, Boston, 2022 | | 2022 |
| Setting up success in the clinic through semi-mechanistic translational modelling J Dickinson, HB Mistry, J Quant, HJ Huber AAPS PharmSci 360, Boston, 2022 | | 2022 |
| Development of a methodology to enable non linear in vitro in vivo correlation for complex long acting injections J Dickinson, C Patterson, P Gajjar, PA Dickinson Quantitative Systems Pharmacology Conference 2022 (QSPC2022), Leiden, 2022 | | 2022 |
| Early understanding of PK/PD: setting up success in development? J Dickinson ELRIG Drug Discovery, Alderley Park, 2021 | | 2021 |
| Development of a methodology to enable non linear in vitro in vivo correlation for complex long acting injections J Dickinson, C Patterson, P Gajjar, PA Dickinson AAPS PharmSci 360, Philadelphia, 2021 | | 2021 |
| Analysis of patient derived xenograft studies in Oncology drug development: impact on design and interpretation of future studies J Dickinson, M de Matas, PA Dickinson, HB Mistry Pharmacokinetics U.K (PKUK), Manchester, 2018 | | 2018 |
Paul A DickinsonSeda Pharmaceutical Development ServicesVerifierad e-postadress på sedapds.com
